TABLE C-4a Program Cost Estimates: Annual Costs per 1,000 HIV (+) Patients by Treatment Category (using New Jersey Department of Health and Johns Hopkins cost estimates) for Medical Surveillance, Prophylaxis, and Treatment

 

 

New Jersey Dept. of Health

Johns Hopkins

Treatment Categorya

Number of Patients/1,000 Patientsb

Annual Cost/patient

Total

Annual Cost/Patient

Total

1

500

$1,6%

$ 838,000

$ 775

$ 387,500

2

300

6,146

1,843,800

3,620

1,086,000

3

150

6,097

914,550

3,736

560,400

4

50

7,304

365,200

6,532

326,600

Total (1,000)

 

 

3,961,550

 

2,360,500

a Treatment categories: 1, CD4+ cells >500-medical monitoring; 2, CD4+ cells 200-500-treatment with zidovudine; 3, CD4+ cells < 200-treatment with zidovudine, prophylaxis with trimethoprim-sulfamethoxazole; 4, CD4+ cells < 200-treatment with zidovudine, prophylaxis with aerosolized pentamidine.

b Distribution of HIV (+) individuals among treatment categories. This proportion is derived from the New Jersey data but is consistent with the Johns Hopkins AIDS Service experience for all adult patients. HIV (+) women may be disproportionately represented in the earlier treatment categories.

TABLE C-4b Program Cost Estimates: Annual Costs for All HIV (+) Individuals in New Jersey (using New Jersey Department of Health and Johns Hopkins cost estimates) for Medical Surveillance, Prophylaxis, and Treatment

 

 

New Jersey Dept. of Health

Johns Hopkins

Treatment Category

Total Patients

Annual Cost/Patient

Total (in millions)

Annual Cost/Patient

Total (in millions)

1

35,000

$1,676

$ 58,660

$ 775

$ 27,125

2

21,000

6,146

129,066

3,620

76,020

3

10,500

6,097

64,019

3,736

39,228

4

3,500

7,304

25,564

6,532

22,862

Total

70,000

 

277,309

 

165,235



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement